A Perspective on the Impact of Advanced Glycation End Products in the Progression of Diabetic Nephropathy.

In 2007, diabetes affected around 244 million people across the globe. The number of diabetics worldwide is projected to reach 370 million by 2030. With diabetes incidence reaching epidemic proportions globally, diabetic nephropathy (DN) has emerged as one of the most difficult health conditions. Although therapeutic approaches such as rigorous blood glucose and blood pressure management are successful in preventing DN, they are far from ideal, and the number of diabetic patients with endstage renal disease continues to grow. As a result, a unique treatment approach for DN should be devised. There is mounting evidence that advanced glycation end products (AGEs), senescent macro protein derivatives generated at an accelerated pace in DN, contribute to DN by generating oxidative stress. The purpose of this article is to discuss the pathophysiological significance of AGEs and their receptor in DN.